Small Molecule Inhibitors of Interleukin-4
This technology introduces the first small-molecule inhibitor for Interleukin-4 (IL-4), a critical regulator of inflammation associated with conditions like asthma, allergies, and cancer. Existing antibody-based treatments have faced limitations in clinical trials, making this small-molecule inhibitor a significant breakthrough. By disrupting IL-4 signaling in cells with a nicotinonitrile scaffold-based compound, this innovation opens doors for novel treatments of immune disorders and paves the way for drug discovery targeting challenging proteins.
Researchers
-
small molecule inhibitors of interleukin-4
United States of America | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.